Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rod Hughes

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Therapeutic Advances in Respiratory Disease|June 6, 2024
Relationships between symptoms and lung function in asthma and/or chronic obstructive pulmonary disease in a real-life setting: the NOVEL observational longiTudinal studYAlberto Papi, Rod Hughes, Ricardo Del Olmo, et al.
BMJ Open Respiratory Research|March 6, 2026
Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABAMohd Nubli Mustapa, Rod Hughes, Tina J Jensen, et al.
Clinical and Experimental Rheumatology|February 24, 2022
Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies: incidence using different testing criteria, and case seriesVikram M K Joseph, Emily C Rose, Christopher J Edwards, et al.
International Journal of Chronic Obstructive Pulmonary Disease|October 1, 2025
Phase 2a, Randomized Trial of Mitiperstat Versus Placebo in Patients with COPD at High Risk of Exacerbation (CRESCENDO)Rod Hughes, Wayne Brailsford, João Ferreira, et al.
The Journal of Rheumatology|February 4, 2014
Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: outcomes of importance for patients with PMRSarah L Mackie, Seher Arat, Jose da Silva, et al.
Annals of the American Thoracic Society|September 17, 2025
Prevalence and Clinical Characteristics of Persistent Airflow Limitation in the NOVELTY CohortRichard Beasley, Rod Hughes, Alvar Agusti, et al.
Scientific Reports|July 12, 2023
PhysVENeT: a physiologically-informed deep learning-based framework for the synthesis of 3D hyperpolarized gas MRI ventilationJoshua R Astley, Alberto M Biancardi, Helen Marshall, et al.
The Journal of Allergy and Clinical Immunology|January 14, 2026
First-in-human study for londamocitinib (AZD4604), an inhaled, selective JAK1 inhibitorTina Jellesmark Jensen, Camille Riff, Julia Lund, et al.
The Journal of Rheumatology|December 17, 2016
Stiffness Is the Cardinal Symptom of Inflammatory Musculoskeletal Diseases, Yet Still Variably Measured: Report from the OMERACT 2016 Stiffness Special Interest GroupSerena Halls, Premarani Sinnathurai, Sarah Hewlett, et al.
American Journal of Respiratory and Critical Care Medicine|May 16, 2024
A Bispecific Monoclonal Antibody Targeting Psl and PcrV Enhances Neutrophil-Mediated Killing of <i>Pseudomonas aeruginosa</i> in Patients with BronchiectasisMerete B Long, Amy Gilmour, Margaret Kehl, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Therapeutic Advances in Respiratory Disease|June 6, 2024
Relationships between symptoms and lung function in asthma and/or chronic obstructive pulmonary disease in a real-life setting: the NOVEL observational longiTudinal studYAlberto Papi, Rod Hughes, Ricardo Del Olmo, et al.
BMJ Open Respiratory Research|March 6, 2026
Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABAMohd Nubli Mustapa, Rod Hughes, Tina J Jensen, et al.
Clinical and Experimental Rheumatology|February 24, 2022
Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies: incidence using different testing criteria, and case seriesVikram M K Joseph, Emily C Rose, Christopher J Edwards, et al.
International Journal of Chronic Obstructive Pulmonary Disease|October 1, 2025
Phase 2a, Randomized Trial of Mitiperstat Versus Placebo in Patients with COPD at High Risk of Exacerbation (CRESCENDO)Rod Hughes, Wayne Brailsford, João Ferreira, et al.
The Journal of Rheumatology|February 4, 2014
Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: outcomes of importance for patients with PMRSarah L Mackie, Seher Arat, Jose da Silva, et al.
Annals of the American Thoracic Society|September 17, 2025
Prevalence and Clinical Characteristics of Persistent Airflow Limitation in the NOVELTY CohortRichard Beasley, Rod Hughes, Alvar Agusti, et al.
Scientific Reports|July 12, 2023
PhysVENeT: a physiologically-informed deep learning-based framework for the synthesis of 3D hyperpolarized gas MRI ventilationJoshua R Astley, Alberto M Biancardi, Helen Marshall, et al.
The Journal of Allergy and Clinical Immunology|January 14, 2026
First-in-human study for londamocitinib (AZD4604), an inhaled, selective JAK1 inhibitorTina Jellesmark Jensen, Camille Riff, Julia Lund, et al.
The Journal of Rheumatology|December 17, 2016
Stiffness Is the Cardinal Symptom of Inflammatory Musculoskeletal Diseases, Yet Still Variably Measured: Report from the OMERACT 2016 Stiffness Special Interest GroupSerena Halls, Premarani Sinnathurai, Sarah Hewlett, et al.
American Journal of Respiratory and Critical Care Medicine|May 16, 2024
A Bispecific Monoclonal Antibody Targeting Psl and PcrV Enhances Neutrophil-Mediated Killing of <i>Pseudomonas aeruginosa</i> in Patients with BronchiectasisMerete B Long, Amy Gilmour, Margaret Kehl, et al.
Pageof 5